Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the prevention of HIV, developed by Gilead Sciences. The approval of Yeztugo marks a ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk of HIV ...

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding for HIV prevention efforts.

A pickup driver who crashed into a tour van near Yellowstone National Park earlier this month, causing the death of six people, had a blood alcohol level more than twice the legal limit, police said.

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...